Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
26 oct. 2021 08h00 HE
|
Clearmind Medicine
TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
14 oct. 2021 08h00 HE
|
Clearmind Medicine
TORONTO, Ontario, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy
13 oct. 2021 08h00 HE
|
Clearmind Medicine
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
07 oct. 2021 08h00 HE
|
Clearmind Medicine
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
01 oct. 2021 08h00 HE
|
Clearmind Medicine
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
21 sept. 2021 07h00 HE
|
Clearmind Medicine
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
03 août 2021 07h00 HE
|
Clearmind Medicine
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
Clearmind Issues Shareholder Letter
20 juil. 2021 07h00 HE
|
Clearmind Medicine
Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...